|
Monthly transition probabilitiesa
|
Estimate
|
Standard deviation
|
Distribution
|
Data source
|
|---|
|
Hospitalization for HF
| | | | |
|
Add-on dapagliflozin
|
0.005611395
|
0.001533432
|
Beta
|
DAPA-HF trial [10]
|
|
Standard care
|
0.007881397
|
0.001816007
|
Beta
|
|
Cardiovascular death
| | | |
|
Add-on dapagliflozin
|
0.005509456
|
0.001519518
|
Beta
|
|
Standard care
|
0.006698743
|
0.001675218
|
Beta
|
|
Non-cardiovascular death
| | | |
|
Add-on dapagliflozin
|
0.005509456
|
0.001519518
|
Beta
|
|
Standard care
|
0.001312441
|
0.000743514
|
Beta
|
|
Cost parameters (per month)
|
Cost (US$)
|
Range
|
Distribution
|
Data source
|
|---|
|
Drug costs of dapagliflozin (10 mg once daily)
|
28.6
|
± 14.3
|
Gamma
|
NHIRD
|
|
Stable HF
|
450
|
± 225
|
Gamma
|
|
Emergency visit or hospitalization for HF
|
2887
|
± 1443.5
|
Gamma
|
|
Cost during month before cardiovascular death
|
3430
|
± 1715
|
Gamma
|
|
Cost during month before non-cardiovascular death
|
3390
|
± 1695
|
Gamma
|
|
Health utilities parameters
|
Estimate
|
Standard error
|
Distribution
|
Data source
|
|---|
|
Stable HF
|
0.770
|
0.016
|
Beta
|
[19]
|
|
Utility decrement associated with aging (per year increase)
|
− 0.0016
|
0.0001
|
Beta
|
|
Utility decrement of emergency visit or hospitalization related to HF
|
− 0.321
|
0.02
|
Beta
|
- DAPA-HF dapagliflozin in patients with heart failure and reduced ejection fraction, HF heart failure, NHIRD National Health Insurance Research Database
- aThe monthly transition probabilities were transformed as follows: (1) Probability (obtained from DAPA-HF trial) transformed to a rate: [− ln (1 − p)]/t. (2) Rate transformed to a probability (monthly transition probability applied in the analyses): 1 − exp(– rt), where r is the rate, p is the probability, and t is the time
